Abbott MediaRoom http://abbott.mediaroom.com/ Abbott to Present at J.P. Morgan Healthcare Conference http://abbott.mediaroom.com/2017-12-04-Abbott-to-Present-at-J-P-Morgan-Healthcare-Conference Mon, 04 Dec 2017 09:00:00 -0500 http://abbott.mediaroom.com/2017-12-04-Abbott-to-Present-at-J-P-Morgan-Healthcare-Conference Abbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan http://abbott.mediaroom.com/2017-11-06-Abbotts-MitraClip-Approved-as-First-Transcatheter-Mitral-Valve-Repair-Device-in-Japan - First minimally invasive device to treat people in Japan with common leaky heart valve for whom surgery is too risky Mon, 06 Nov 2017 08:00:00 -0500 http://abbott.mediaroom.com/2017-11-06-Abbotts-MitraClip-Approved-as-First-Transcatheter-Mitral-Valve-Repair-Device-in-Japan Analysis Shows Better Health Outcomes and Cost Effectiveness for Coronary Intervention Using Abbott's Fractional Flow Reserve (FFR) Diagnostic in Patients with Stable Coronary Artery Disease http://abbott.mediaroom.com/Analysis-Shows-Better-Health-Outcomes-and-Cost-Effectiveness-for-Coronary-Intervention-Using-Abbotts-Fractional-Flow-Reserve-FFR-Diagnostic-in-Patients-with-Stable-Coronary-Artery-Disease - After three years, patients who underwent FFR-guided percutaneous coronary intervention (PCI) in combination with medical therapy had significantly fewer major adverse cardiac events compared to patients who received medical therapy alone Thu, 02 Nov 2017 12:10:00 -0400 http://abbott.mediaroom.com/Analysis-Shows-Better-Health-Outcomes-and-Cost-Effectiveness-for-Coronary-Intervention-Using-Abbotts-Fractional-Flow-Reserve-FFR-Diagnostic-in-Patients-with-Stable-Coronary-Artery-Disease Abbott Announces FDA Clearance for its Alinity™ ci-series Next-generation Diagnostic Systems http://abbott.mediaroom.com/2017-10-31-Abbott-Announces-FDA-Clearance-for-its-Alinity-TM-ci-series-Next-generation-Diagnostic-Systems - Innovative, harmonized solutions for chemical chemistry and immunoassay testing will help laboratories and hospital systems achieve measurably better healthcare performance Tue, 31 Oct 2017 09:00:00 -0400 http://abbott.mediaroom.com/2017-10-31-Abbott-Announces-FDA-Clearance-for-its-Alinity-TM-ci-series-Next-generation-Diagnostic-Systems Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease with XIENCE Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery http://abbott.mediaroom.com/2017-10-30-Analysis-of-Landmark-Study-Showed-Patients-Treated-for-Left-Main-Coronary-Artery-Disease-with-XIENCE-Stent-Felt-Better-Faster-and-Had-Similar-Long-Term-Outcomes-to-Open-Heart-Surgery - Long-term health and quality of life were similar at three years for patients receiving a XIENCE stent and patients who underwent surgery Mon, 30 Oct 2017 13:20:00 -0400 http://abbott.mediaroom.com/2017-10-30-Analysis-of-Landmark-Study-Showed-Patients-Treated-for-Left-Main-Coronary-Artery-Disease-with-XIENCE-Stent-Felt-Better-Faster-and-Had-Similar-Long-Term-Outcomes-to-Open-Heart-Surgery